Pharmaceutical

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.

Apr 23, 2024 - 00:00
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.
Read the original article

Tags:

Previous Article

Life goals and their changes drive success

Next Article

AlphaMedix by Orano Med for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NE...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: For Parkinson’s disease, advances spurred by Apple Watch offer a glimmer of hope

STAT+: For Parkinson’s disease, advances spurred by App...

Oct 24, 2023

Opinion: Former Surgeon General Jerome Adams: Prioritize new antivirals for Covid

Opinion: Former Surgeon General Jerome Adams: Prioritiz...

Jun 22, 2023

Clues from mice could help explain why women face a higher risk of autoimmune disorders

Clues from mice could help explain why women face a hig...

Feb 1, 2024